61 results about "Corneal epithelial cell" patented technology

The invention relates to recombinant III-type humanized collagen and application of a composition containing the same to eyes. The invention provides an application of recombinant III type humanized collagen in preparation of a product for preventing and / or treating eye inflammation, a composition containing the recombinant III type humanized collagen, and an application of the composition in preparation of a product for preventing and / or treating eye inflammation and / or eye dryness. The recombinant III-type humanized collagen and the composition containing the recombinant III-type humanized collagen can obviously promote updating and repairing of corneal epithelial cells, and meanwhile, can inhibit release of inflammatory mediators, enhance eye tissue barriers, enhance tear film stability and relieve eye inflammation and eye dryness.

The invention provides a methacrylic anhydride modified sclera extracellular matrix repair material and a curing method thereof, and belongs to the technical field of medical repair materials. The methacrylic anhydride modified sclera extracellular matrix repair material provided by the invention is prepared from the following raw materials: a methacrylic anhydride modified sclera extracellular matrix, methacrylated gelatin, a photoinitiator and a solvent. The sclera extracellular matrix modified by methacrylic anhydride is adopted, methacrylic anhydride contains methacrylic acid, double bonds can be introduced, the sclera extracellular matrix has the photo-initiation polymerization capacity, and in-situ gelling can be carried out at sclera and cornea damage positions under the action of a photoinitiator; the sclera extracellular matrix has good biocompatibility and histocompatibility, so that sclera matrix cells and corneal epithelial cells are adhered and proliferated, and the sutureless repair is realized; the methacrylated gelatin can provide a photo-crosslinking gelatin network under the action of a photoinitiator, so that cell adhesion and proliferation can be promoted, and repair is realized.

The present invention relates to a method for inducing the differentiation of corneal epithelial cells from pluripotent stem cells. More specifically, the present invention relates to a method for autonomously differentiating pluripotent stem cells, such as human iPS cells, into ectodermal cell lineage in a serum-free medium without using feeder cells and inducing the differentiation of the resultant ocular surface ectodermal lineage cells into corneal epithelial cells.

The invention discloses a ferroptosis inhibition research method based on a hypertonic dry eye cell model, and relates to the technical field of xerophthalmia. Comprising the following steps: S1, establishing a hypertonic dry eye cell model, and selecting human corneal epithelial cells to perform hypertonic treatment in a hypertonic culture medium; s2, detecting a ferroptosis marker; performing GPX4 protein expression detection; s2.1, detecting the lipid peroxidation level; s2.2, detecting the iron ion level of the sample; s2.3, observing the mitochondrial morphology of the sample; s3, carrying out an autoserum intervention experiment, and treating the culture media of different groups by using autoserum; s4, data statistics and analysis; by detecting expression of proteins such as a ferroptosis marker GPX4 and the like, it is determined that autoserum can inhibit ferroptosis and improve corneal epithelial cell survival by enhancing GPX4 expression and reducing lipid peroxidation and iron ion level, a scientific basis is provided for further optimization and accurate application, a treatment strategy for xerophthalmia is improved, and the application has a wide application prospect. And a new direction is opened up for mechanism research and personalized treatment of the xerophthalmia in the future.

This invention relates to the use of recombinant type III humanized collagen and compositions comprising thereof in the ocular field. The invention provides the use of recombinant type III humanized collagen in the preparation of products for the prevention and / or treatment of ocular inflammation, and compositions comprising recombinant type III humanized collagen, and the use of these compositions in the preparation of products for the prevention and / or treatment of ocular inflammation and / or dry eye. Recombinant type III humanized collagen and compositions comprising thereof can significantly promote the renewal and repair of corneal epithelial cells, while inhibiting the release of inflammatory mediators, strengthening the ocular tissue barrier, enhancing tear film stability, and relieving ocular inflammation and dry eye.

The present invention relates to superoxide dismutase and its use in the prevention or treatment of dry eye. More specifically, the present invention relates to a pharmaceutical composition or a treatment method for preventing or treating dry eye. According to the compositions and methods of the present invention, an increase in the secretion amount selected from tear fluid can be achieved; the tear film rupture time is prolonged; minimizing ocular surface damage; goblet cells in the conjunctiva are protected; the number of immune cells and inflammatory cell factors in cornea and conjunctiva is reduced; reduction of oxidative stress in cornea, conjunctiva and lacrimal gland; and a reduction in corneal epithelial cell apoptosis, thereby being effectively used in the prevention or treatment of dry eye.

The invention belongs to the technical field of biomedicine, and relates to a novel application of 3-O-methyl chrysotoxin, in particular to an application of 3-O-methyl chrysotoxin in preparation of a medicine for treating xerophthalmia. The core of the 3-O-methyl chrysotoxin disclosed by the invention is that the 3-O-methyl chrysotoxin effectively relieves corneal epithelial cell injury induced by hyperosmosis and inhibits oxidative stress and proinflammatory factor release by activating an EGFR (Epidermal Growth Factor Receptor) signal channel. In-vitro and in-vivo experiments prove that the composition can remarkably enhance cell activity, reduce apoptosis and active oxygen accumulation and repair the steady state of a tear film. The compound is applied to preparation of xerophthalmia drugs and has important clinical value.

The present application belongs to the technical field of contact lenses, and provides a contact lens containing PDRN and a preparation method thereof. The contact lens is pretreated to obtain a plasma lens; the plasma lens is sequentially soaked in a first PDRN solution, a hyaluronic acid solution, a second PDRN solution and a taurine solution to obtain a semi-finished lens; and the semi-finished lens is crosslinked to obtain the contact lens containing PDRN. Through the design of a multi-layer structure, the present application realizes the synchronous and synergistic implantation of PDRN, hyaluronic acid and taurine in the contact lens. Among them, PDRN activates the A2A adenosine receptor signaling pathway, plays a core therapeutic role in promoting corneal epithelial cell proliferation, inhibiting the release of inflammatory factors and accelerating tissue repair; hyaluronic acid plays a role in lubricating and protecting the cornea; and taurine can scavenge active oxygen free radicals and reduce oxidative stress damage.

The application relates to the technical field of ophthalmic material preparation, and particularly discloses a kind of biopolymer membranes, a preparation method thereof and application in ophthalmic surgery.The biopolymer membrane comprises the following raw material components by weight: polyvinyl alcohol 5-10 parts;gelatin 3-6 parts;sodium lignosulfonate 10-20 parts;carboxymethyl cellulose 3-6 parts;natural extract 1-3 parts;water 200-300 parts.Studies have shown that the biopolymer membrane can promote the proliferation of human corneal epithelial cells;therefore, it has important application value when used in ophthalmic surgery for the treatment of ocular surface damage.

The invention discloses application of EPO (erythropoietin) in preparation of a medicine for preventing and treating corneal injury, belongs to the technical field of medicines, and focuses on innovative application of EPO in preparation of the medicine for preventing and treating corneal injury. The cornea is used as a key structure of eyes and is easily damaged by various factors such as mechanical trauma, chemical injury, infection and diabetes, and more than ten millions of people in the world are troubled by cornea blindness. The invention finds that EPO has a remarkable treatment effect on corneal injury, and can promote proliferation and migration of corneal epithelium and stromal cells, increase the generation of extracellular matrix and enhance the tolerance of corneal epithelium cells and corneal stromal cells to high-level sugar. The medicine can be a self-freeze-drying preparation or a solution preparation, the administration modes are diversified, and various eye local injection, eye drop, gene therapy and the like are covered. Refined treatment schemes are provided for corneal injuries of different pathogenesis, a new way is developed for treatment of the corneal injuries, the corneal blindness rate is expected to be reduced, and the development of ophthalmic medicine is promoted.

This invention discloses the application of low-concentration topical anesthetics in ophthalmic surgery, relating to the field of low-concentration topical anesthetic application technology, including the following specific application process: confirming the patient's basic surgical condition before administration; selecting anesthetic drugs and optimizing the administration concentration; performing administration according to the specific situation; real-time dynamic monitoring and adjustment of the administration dosage; gradually reducing the drug and transitioning to withdrawal. This invention improves drug safety and patient compliance while ensuring analgesic effects by optimizing anesthetic drug concentration and administration method. Furthermore, by using topical anesthetics at concentrations lower than conventional anesthetics for local administration after ophthalmic surgery, it can effectively relieve postoperative pain, discomfort, and foreign body sensation while significantly reducing toxic effects on corneal epithelial cells, reducing delayed corneal healing, dry eye, and corneal damage. It is effectively applicable to analgesia management after pterygium excision, refractive surgery, and other common ophthalmic surgeries, and has good clinical application value.

The invention discloses a small-molecule active aldehyde scavenger-albumin coupling medicine as well as a preparation method and application of the small-molecule active aldehyde scavenger-albumin coupling medicine. The coupling drug comprises a) the small molecule active aldehyde scavenger compound or the derivative thereof and b) albumin, and the albumin comprises at least one of human serum albumin, recombinant albumin, bovine serum albumin, ovalbumin and mouse serum albumin. The medicine is further prepared into an ophthalmic preparation, the retention time of the medicine in the cornea is prolonged, the in-vitro active aldehyde removal efficiency of the medicine is improved to 1.5 times of that of NS-2, expression (larger than or equal to 50%) of a human corneal epithelial cell inflammatory factor IL-6 is remarkably inhibited, and irritation to eyes is avoided. Through the synergistic effect of long-acting slow release of the albumin carrier and targeted removal of NS, the technical defects that a traditional xerophthalmia medicine is short in effect and single in mechanism are overcome, and a definite clinical transformation value is achieved.

The invention belongs to the technical field of medicine preparation, and provides an ophthalmic external preparation and a preparation method thereof. According to the ophthalmic external preparation, curcumin included by hydroxypropyl-beta-cyclodextrin loaded on exosome modified by polylysine is adopted as an effective component. The preparation can improve the drug concentration of cornea tissues and realize accurate delivery of ocular surfaces; meanwhile, the exosome and curcumin form a synergistic effect, so that the release of proinflammatory factors such as IL-1beta and TNF-alpha can be inhibited, the secretion of goblet cell mucoprotein and the proliferation of corneal epithelial cells can be promoted, and the tear film rupture time is prolonged; in addition, the preparation is excellent in biocompatibility, free of ocular surface stimulation reaction and high in safety.

The invention relates to the technical field of biological material preparation, and particularly discloses hyaluronic acid hydrogel as well as a preparation method and application thereof in preparation of a corneal injury repair material. The preparation method of the hyaluronic acid hydrogel comprises the following steps: S1, preparing a hyaluronic acid solution; s2, adding a cross-linking agent into the hyaluronic acid solution, and adjusting to acidic pH to obtain a solution A; s3, adding a carboxyl activator into the solution A, and stirring to obtain hyaluronic acid hydrogel; a preparation method of the hyaluronic acid solution in the step S1 comprises the following steps: taking hyaluronic acid, adding the hyaluronic acid into the traditional Chinese medicine extracting solution, and uniformly stirring to obtain the hyaluronic acid solution. Researches show that the hyaluronic acid hydrogel prepared by the method disclosed by the invention has the effect of promoting proliferation of corneal epithelial cells; therefore, the material has important application value when being used as a corneal injury repair material.

The present invention belongs to the field of biotechnology, and specifically relates to a duck corneal epithelial cell suspension cell line, its construction method, and application. The present invention is the first to isolate and obtain adult corneal epithelial cells from ducks and successfully suspend and domesticate them. The cell line is named Duck Corneal Epithelial Suspension Cells (DCE-S) and was deposited in the China Center for Type Culture Collection at Wuhan University, Wuhan, China on June 28, 2024, with the deposit number CCTCC NO: C2024189. The cell line is easy to culture, grows rapidly, can be stably passaged, and has a high cell density of 6 to 8×10 6 cells / mL, exhibiting individually dispersed growth, plump morphology, uniform size, and high cell viability, making it suitable for serum-free suspension culture in bioreactors. This cell line can be used to culture, isolate, and detect avian viruses, prepare avian vaccines, and screen for drugs used to prevent or treat diseases caused by avian viral infections.

The invention discloses an application of a snail mucus gel purified product in preparation of a medicine for promoting corneal epithelium injury repair. The snail mucus extract is snail mucus gel purified product Z1 subtype (s-GAG Z1), and is obtained through cell and animal experiments: when the concentration of the s-GAG Z1 is 0.05 mg / mL, the cell proliferation speed is high; after the s-GAG Z1 is applied to a mouse, the cornea healing speed is higher / faster, the inflammatory cells are more / fewer, and the epithelium growth is better / better, which indicates that the s-GAG Z1 has the effects of promoting the proliferation of corneal limbal stem cells, promoting the regeneration of corneal epithelium cells and resisting inflammation in the corneal epithelium injury healing process, thereby accelerating the corneal injury healing speed. The therapeutic effect and mechanism of the s-GAG Z1 in the cornea are discussed for the first time, an experimental basis and a potential medicine are provided for clinically treating corneal ulcer, keratitis, xerophthalmia, diabetes-related keratopathy and other related corneal diseases, and toxic and side effects are avoided.

The invention provides a means for treating a disease involving damage of corneal epithelial cells. In particular, the invention provides a composition for use in treating a disease involving damage of corneal epithelial cells, as well as a use thereof. The composition includes (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalene-1-yl)acetamide, a pharmaceutically acceptable salt thereof, or a solvate thereof.

The invention provides oxygen-enriched eye drops based on oxygen-containing lipidosome and application of the oxygen-enriched eye drops. The preparation method comprises the following steps: firstly, preparing blank liposome powder through a film dispersion-freeze drying technology, carrying out oxygenation treatment on the blank liposome powder to prepare oxygen-containing liposome, and then mixing the oxygen-containing liposome with sodium hyaluronate eye drops to obtain the oxygen-enriched eye drops. According to the oxygen-enriched eye drops, the permeability of oxygen in corneal tissues is improved, proliferation of corneal epithelial cells is remarkably promoted, and the apoptosis process of the corneal epithelial cells is delayed. The oxygen-enriched eye drops can promote repair after corneal epithelium injury.

The present invention discloses a preparation method and application of a metal ion coordination gel, wherein the gel material comprises: H-(RADA)4 and (RADA)4 gel stock solution, through histidine (His) and Cu 2+ The resulting complex solution, H-(RADA)4-Cu, is then mixed evenly with the (RADA)4 solution and added to a PBS buffer solution to form a stable gel. This gel exhibits excellent biocompatibility, promotes corneal epithelial cell repair, inhibits the growth of Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli), and is effective in treating keratitis.

According to the application of the doxycycline and the compound composition of the doxycycline in preparation of the corneal injury repairing medicine, corneal collagenase is inhibited through the doxycycline, repairing of corneal epithelium is facilitated, and the oculentum preparation can act on cornea more enduringly, so that corneal repairing of alkali burn patients, dry eye patients and ocular surface injury patients is promoted, and the curative effect of the oculentum preparation is improved. According to the eye ointment, corneal epithelial cells can be effectively treated, regeneration and healing of the corneal epithelial cells are accelerated, hormones and non-steroidal anti-inflammatory components are added, ocular surface inflammatory response can be specifically inhibited, symptoms such as red and swollen eyes and pain can be relieved, the repairing effect of corneal epithelium can be enhanced, all the components are uniformly dispersed in the eye ointment by optimizing the preparation process, the stability of the eye ointment is guaranteed, and the eye ointment has good application prospects. The phenomena of layering, devitrification and the like are not easy to occur in the storage process, and stable and reliable product quality is ensured.

The invention provides a method for constructing a tissue engineered cornea based on human amniotic epithelial stem cells and application, and belongs to the technical field of biology. The method comprises the following steps: 1) culturing human amniotic epithelial stem cells in a corneal epithelial cell induced differentiation culture medium to obtain human corneal epithelial cell-like cells; culturing the human amniotic epithelial stem cells in a corneal stroma cell induced differentiation culture medium to obtain corneal stroma cells; and 2) respectively inoculating the human corneal epithelial cell-like cells and corneal stroma cells obtained in the step 1) on the surface and inside of an acellular corneal stroma scaffold, and co-culturing for 5 days to construct the tissue engineered cornea. According to the method, the two corneal cells derived from the human amniotic epithelial stem cells are simultaneously inoculated to the human decellularized corneal stroma for the first time, the tissue-engineered cornea is successfully constructed, in addition, the corneal cells obtained through differentiation can be inoculated to various types of biological materials such as hydrogel, and the tissue-engineered cornea is obtained. Wider application possibility is provided for developing various novel artificial cornea products.

The invention provides application of Mafb as a target spot in promotion of diabetic corneal epithelium injury repair, and belongs to the technical field of biological medicine. According to the application, the Mafb gene is taken as a treatment target, the repair speed of corneal epithelium injury can be obviously accelerated by over-expressing the Mafb gene in the cornea of a diabetic patient, and the expression levels of stem cell markers and cell proliferation markers in corneal epithelium tissues are obviously up-regulated. The invention also provides a recombinant adeno-associated virus AAV9-Mafb for overexpressing the Mafb gene, and the AAV9-Mafb can significantly recover the function of the corneal limbal stem cells of the diabetic mouse and promote the proliferation of corneal epithelial cells, thereby accelerating the repair of corneal epithelium injury of the diabetic mouse.

The invention discloses application of mesenchymal stem cell apoptosis vesicles in preparation of a medicine for treating dry eyes. The human umbilical cord-derived mesenchymal stem cell apoptosis vesicles are applied to preparation of the medicine for treating the dry eye for the first time, the mesenchymal stem cell apoptosis vesicles have the effects of promoting repair and regeneration of ocular surface cells such as corneal epithelial cells and lacrimal gland cells, can inhibit expression of proinflammatory factors and increase expression of anti-inflammatory factors, and are relatively simple and convenient to prepare and low in cost. Side effects are small and curative effects are high. Under the condition that artificial tears and anti-inflammatory drugs for clinically treating the dry eye at present have certain limitations, the mesenchymal stem cell apoptosis vesicles are used as a therapy with immunoregulation and regeneration repair capabilities, and a new thought is provided for treatment of the dry eye.

The invention relates to the field of biological medicines, in particular to application of an anoxic mesenchymal stem cell exosome in preparation of a medicine for promoting corneal epithelium injury healing. In-vivo and in-vitro experiments prove that the hypoxia mesenchymal stem cell exosome can remarkably restore inhibition on corneal epithelium injury healing under a hypertonic condition in vivo and in vitro, can remarkably promote proliferation and migration of human corneal epithelium cells in vitro, can promote corneal epithelium injury healing in vivo, has a good treatment effect on corneal epithelium injury, and can be used for treating corneal epithelium injury. Good application prospects are realized.

This invention relates to a small molecule compound composition and its applications, belonging to the field of biotechnology. The small molecule compound composition of this invention includes NU7441, GW9662, and D609, or their stereoisomers. This invention is the first to discover that this small molecule compound combination can effectively inhibit oxidative damage to corneal epithelial cells caused by hyperosmolarity and significantly improve the survival rate of corneal epithelial cells. In vivo animal experiments show that, compared with the control group, the experimental group of mice injected with scopolamine-induced dry eye model mice, given eye drops containing the small molecule compound combination, showed significantly reduced corneal defects and increased tear secretion. The small molecule compound combination can effectively prevent corneal epithelial damage, has high efficacy, and no obvious drug toxicity. This small molecule compound combination may become a potent and effective drug for the clinical treatment of dry eye in the future.

The invention relates to a small molecule compound composition and application thereof, and belongs to the technical field of biology. The small molecule compound composition provided by the invention comprises NU7441, GW9662 and D609 or stereoisomers thereof. It is found for the first time that the small molecule compound combination can effectively inhibit oxidative damage caused by hypertonic to corneal epithelial cells, and the survival rate of the corneal epithelial cells is remarkably increased. Animal in-vivo experiments show that compared with a control group, an experimental group which is subjected to injection of scopolamine dry eye model mice and is subjected to eye drop of the small molecule compound combination eye drop at the same time has the advantages that corneal defects are obviously reduced, tear secretion is increased, the small molecule compound combination can effectively prevent corneal epithelium injury, the drug effect is relatively high, and no obvious drug toxicity exists; the small molecule compound combination may become a strong and effective medicine for clinically treating dry eye in the future.

The present invention addresses the problem of providing a novel therapeutic agent that is effective against diseases involving stratified squamous epithelial cells such as dry eye syndrome. The present invention is an agent for promoting normal differentiation / maturation of stratified squamous epithelial cells, which comprises a secretion of mesenchymal stem cells. It is preferable that the secretions not include animal serum, that the mesenchymal stem cells be adipose-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, or bone marrow-derived mesenchymal stem cells, and that the stratified squamous epithelial cells be at least one selected from the group consisting of corneal epithelial cells, conjunctival epithelial cells, epidermal keratinocytes, oral epithelial cells, epiglottic epithelial cells, esophageal epithelial cells, vaginal epithelial cells, vocal fold epithelial cells, nasal epithelial cells, and nasal vestibular epithelial cells.

The invention relates to a construction method of tissue engineering corneal epithelial cells. The construction method comprises the following steps: obtaining corneal limbus tissue blocks; digesting the tissue block, and separating to obtain epithelial cells of the tissue block; the method comprises the following steps: attaching epithelial cells to ultrathin amniotic membrane-umbilical cord derived mesenchymal stem cells, culturing in an SHEM culture medium, changing the SHEM culture medium once every two days, culturing for a period of time, and culturing the epithelial cells for a period of time by using a gas-liquid interface culture method to promote the multi-layer growth of the epithelial cells, thereby obtaining the tissue engineering corneal epithelial cells. Through a controllable preparation scheme, the amniotic membrane carrier with a certain thickness is obtained so as to increase the transparency of the amniotic membrane carrier, meanwhile, the matrix surface of the amniotic membrane carrier is inoculated with MSC, the healthy corneal limbus matrix microenvironment of a human body is simulated, damaged corneal limbus tissue / corneal epithelium is better repaired or regenerated, and the ocular surface microenvironment is improved. The produced ultrathin amnion combined mesenchymal stem cell carrier can obviously improve the effect of a tissue engineering corneal epithelium transplantation operation.

According to the ascorbyl palmitate prodrug micelle and the preparation method and application thereof, when the AP (at) PFPP polymer prodrug micelle is prepared, the micelle with the optimal size and particle size distribution can be formed when the molar ratio of FPBA to AP is 1: 2, and an in-vitro cell experiment shows that the AP (at) PFPP micelle can remove excessive ROS in cells and protect mitochondrial membrane potential; and human corneal epithelial cells (HECs) are protected from oxidative stress injury caused by hypertonic. Experimental results of a dry eye mouse model prove that the AP-PFPP micelle can effectively treat the dry eye, and the AP-PFPP prodrug micelle provides a new thought for the treatment of the dry eye.

The present invention relates to the use of a green oat extract for the manufacture of a composition for the prevention and / or treatment of dry eye syndrome. The composition comprising the green oat extract of the present invention is used for preventing and / or treating the symptoms of dry eye syndrome by promoting tear secretion, repairing corneal epithelial cell damage, slowing lacrimal acinus cell apoptosis and / or maintaining the normal function of the lacrimal gland.